IQVIA (IQV) 10-Q 27 Oct 22 2022 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2022	Oct. 21, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-35907
Entity Registrant Name	IQVIA HOLDINGS INC.
Entity Incorporation, State	DE
Entity Tax Identification Number	27-1341991
Entity Address, Street	4820 Emperor Blvd.
Entity Address, City	Durham
Entity Address, State	NC
Entity Address, Postal Zip Code	27703
City Area Code	919
Local Phone Number	998-2000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of Each Class	Common Stock, par value $0.01 per share
Trading Symbol	IQV
Name of Each Exchange on which Registered	NYSE
Entity Common Stock, Shares Outstanding		185,740,023
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001478242
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenues	$ 3,562	$ 3,391	$ 10,671	$ 10,238
Cost of revenues, exclusive of depreciation and amortization	2,321	2,253	6,975	6,869
Selling, general and administrative expenses	517	498	1,488	1,422
Depreciation and amortization	248	336	773	1,002
Restructuring costs	4	2	15	15
Income from operations	472	302	1,420	930
Interest income	(4)	(2)	(7)	(4)
Interest expense	108	92	288	285
Loss on extinguishment of debt	0	1	0	25
Other expense (income), net	8	(62)	51	(128)
Income before income taxes and equity in (losses) earnings of unconsolidated affiliates	360	273	1,088	752
Income tax expense	70	12	212	104
Income before equity in (losses) earnings of unconsolidated affiliates	290	261	876	648
Equity in (losses) earnings of unconsolidated affiliates	(7)	0	(12)	5
Net income	283	261	864	653
Net income attributable to non-controlling interests	0	0	0	(5)
Net income attributable to IQVIA Holdings Inc.	$ 283	$ 261	$ 864	$ 648
Earnings per share attributable to common stockholders:
Basic (in dollars per share)	$ 1.52	$ 1.36	$ 4.59	$ 3.38
Diluted (in dollars per share)	$ 1.49	$ 1.34	$ 4.52	$ 3.32
Weighted average common shares outstanding:
Basic (in shares)	186.5	191.5	188.3	191.5
Diluted (in shares)	189.4	195.3	191.3	195

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 283	$ 261	$ 864	$ 653
Comprehensive income adjustments:
Unrealized gains (losses) on derivative instruments, net of income tax expense of $2, $—, $10, $—	6	(4)	29	0
Defined benefit plan adjustments, net of income tax expense of $2, $—, $2, $—	10	0	4	0
Foreign currency translation, net of income tax expense of $84, $28, $195, $66	(218)	(117)	(539)	(237)
Reclassification adjustments:
Reclassifications on derivative instruments included in net income, net of income tax benefit of $—, $1, $4, $2	1	3	14	7
Comprehensive income	82	143	372	423
Comprehensive income attributable to non-controlling interests	0	0	0	(5)
Comprehensive income attributable to IQVIA Holdings Inc.	$ 82	$ 143	$ 372	$ 418

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Unrealized (losses) gains on derivative instruments, income tax (benefit) expense	$ 2	$ 0	$ 10	$ 0
Defined benefit plan adjustments, income tax (benefit) expense	2	0	2	0
Foreign currency translation, income tax expense (benefit)	84	28	195	66
(Gain) losses on derivative instruments included in net income, income tax expense	$ 0	$ 1	$ 4	$ 2

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,274	$ 1,366
Trade accounts receivable and unbilled services, net	2,640	2,551
Prepaid expenses	176	156
Income taxes receivable	47	58
Investments in debt, equity and other securities	87	111
Other current assets and receivables	528	521
Total current assets	4,752	4,763
Property and equipment, net	507	497
Operating lease right-of-use assets	333	406
Investments in debt, equity and other securities	64	76
Investments in unconsolidated affiliates	87	88
Goodwill	13,177	13,301
Other identifiable intangibles, net	4,718	4,943
Deferred income taxes	97	124
Deposits and other assets	488	491
Total assets	24,223	24,689
Current liabilities:
Accounts payable and accrued expenses	2,971	2,981
Unearned income	1,842	1,825
Income taxes payable	124	137
Current portion of long-term debt	151	91
Other current liabilities	165	207
Total current liabilities	5,253	5,241
Long-term debt, less current portion	12,243	12,034
Deferred income taxes	560	410
Operating lease liabilities	259	313
Other liabilities	561	649
Total liabilities	18,876	18,647
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock and additional paid-in capital, 400.0 shares authorized as of September 30, 2022 and December 31, 2021, $0.01 par value, 256.3 shares issued and 185.8 shares outstanding as of September 30, 2022; 255.8 shares issued and 190.6 shares outstanding as of December 31, 2021	10,853	10,777
Retained earnings	3,107	2,243
Treasury stock, at cost, 70.5 and 65.2 shares as of September 30, 2022 and December 31, 2021, respectively	(7,715)	(6,572)
Accumulated other comprehensive loss	(898)	(406)
Total stockholders’ equity	5,347	6,042
Total liabilities and stockholders’ equity	$ 24,223	$ 24,689

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Millions	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, shares authorized (in shares)	400	400
Common stock, par value, ( in usd per share)	$ 0.01	$ 0.01
Common stock, shares issued (in shares)	256.3	255.8
Common stock, shares outstanding (in shares)	185.8	190.6
Treasury stock, shares (in shares)	70.5	65.2

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities:
Net income	$ 864	$ 653
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization	773	1,002
Amortization of debt issuance costs and discount	11	14
Stock-based compensation	136	128
Losses (earnings) from unconsolidated affiliates	12	(5)
Loss (gain) on investments, net	35	(9)
Benefit from deferred income taxes	(52)	(83)
Changes in operating assets and liabilities:
Change in accounts receivable, unbilled services and unearned income	(88)	663
Change in other operating assets and liabilities	9	(113)
Net cash provided by operating activities	1,700	2,250
Investing activities:
Acquisition of property, equipment and software	(503)	(456)
Acquisition of businesses, net of cash acquired	(1,012)	(994)
Purchases of marketable securities, net	(4)	(9)
Investments in unconsolidated affiliates, net of payments received	(14)	(3)
Proceeds from sale of equity securities	0	5
Other	4	1
Net cash used in investing activities	(1,529)	(1,456)
Financing activities:
Proceeds from issuance of debt	1,250	1,951
Payment of debt issuance costs	(5)	(40)
Repayment of debt and principal payments on finance leases	(86)	(2,068)
Proceeds from revolving credit facility	1,500	410
Repayment of revolving credit facility	(1,600)	(300)
Payments related to employee stock option plans	(70)	(51)
Repurchase of common stock	(1,103)	(202)
Acquisition of Quest's non-controlling interest	0	(758)
Contingent consideration and deferred purchase price payments	(22)	(39)
Net cash used in financing activities	(136)	(1,097)
Effect of foreign currency exchange rate changes on cash	(127)	(41)
Decrease in cash and cash equivalents	(92)	(344)
Cash and cash equivalents at beginning of period	1,366	1,814
Cash and cash equivalents at end of period	$ 1,274	$ 1,470

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Non- controlling Interests
Beginning balance (in shares) at Dec. 31, 2020		254.7	63.5
Beginning balance at Dec. 31, 2020	$ 6,280	$ 3	$ (6,166)	$ 11,092	$ 1,277	$ (205)	$ 279
Increase (Decrease) in Stockholders' Equity
Issuance of common stock (in shares)		0.7
Issuance of common stock	(57)			(57)
Repurchase of common stock (in shares)			(0.3)
Repurchase of common stock	(62)		$ (62)
Stock-based compensation	30			30
Net income	217				212		5
Unrealized gains on derivative instruments, net of tax	6					6
Foreign currency translation, net of tax	(178)					(178)
Reclassification adjustments, net of tax	1					1
Ending balance (in shares) at Mar. 31, 2021		255.4	63.8
Ending balance at Mar. 31, 2021	6,237	$ 3	$ (6,228)	11,065	1,489	(376)	284
Beginning balance (in shares) at Dec. 31, 2020		254.7	63.5
Beginning balance at Dec. 31, 2020	6,280	$ 3	$ (6,166)	11,092	1,277	(205)	279
Increase (Decrease) in Stockholders' Equity
Net income	653
Unrealized gains on derivative instruments, net of tax	0
Defined benefit plan adjustments, net of income tax expense of $2, $—, $2, $—	0
Foreign currency translation, net of tax	(237)
Ending balance (in shares) at Sep. 30, 2021		255.6	64.5
Ending balance at Sep. 30, 2021	5,829	$ 3	$ (6,398)	10,744	1,925	(445)	0
Beginning balance (in shares) at Mar. 31, 2021		255.4	63.8
Beginning balance at Mar. 31, 2021	6,237	$ 3	$ (6,228)	11,065	1,489	(376)	284
Increase (Decrease) in Stockholders' Equity
Issuance of common stock (in shares)		0.2
Issuance of common stock	1			1
Repurchase of common stock (in shares)			(0.2)
Repurchase of common stock	(45)		$ (45)
Stock-based compensation	42			42
Acquisition of Quest's non-controlling interest, net of tax	(709)			(415)		(10)	(284)
Net income	175				175		0
Unrealized gains on derivative instruments, net of tax	(2)					(2)
Foreign currency translation, net of tax	58					58	0
Reclassification adjustments, net of tax	3					3
Ending balance (in shares) at Jun. 30, 2021		255.6	64
Ending balance at Jun. 30, 2021	5,760	$ 3	$ (6,273)	10,693	1,664	(327)	0
Increase (Decrease) in Stockholders' Equity
Issuance of common stock (in shares)		0
Issuance of common stock	4			4
Repurchase of common stock (in shares)			(0.5)
Repurchase of common stock	(125)		$ (125)
Stock-based compensation	48			48
Acquisition of Quest's non-controlling interest, net of tax	(1)			(1)
Net income	261				261		0
Unrealized gains on derivative instruments, net of tax	(4)					(4)
Defined benefit plan adjustments, net of income tax expense of $2, $—, $2, $—	0
Foreign currency translation, net of tax	(117)					(117)	0
Reclassification adjustments, net of tax	3					3
Ending balance (in shares) at Sep. 30, 2021		255.6	64.5
Ending balance at Sep. 30, 2021	$ 5,829	$ 3	$ (6,398)	10,744	1,925	(445)	0
Beginning balance (in shares) at Dec. 31, 2021	190.6	255.8	65.2
Beginning balance at Dec. 31, 2021	$ 6,042	$ 3	$ (6,572)	10,774	2,243	(406)	0
Increase (Decrease) in Stockholders' Equity
Issuance of common stock (in shares)		0.4
Issuance of common stock	(67)			(67)
Repurchase of common stock (in shares)			(1.7)
Repurchase of common stock	(403)		$ (403)
Stock-based compensation	35			35
Net income	325				325
Unrealized gains on derivative instruments, net of tax	30					30
Defined benefit plan adjustments, net of income tax expense of $2, $—, $2, $—	(2)					(2)
Foreign currency translation, net of tax	(40)					(40)
Reclassification adjustments, net of tax	(1)					(1)
Ending balance (in shares) at Mar. 31, 2022		256.2	66.9
Ending balance at Mar. 31, 2022	$ 5,919	$ 3	$ (6,975)	10,742	2,568	(419)	0
Beginning balance (in shares) at Dec. 31, 2021	190.6	255.8	65.2
Beginning balance at Dec. 31, 2021	$ 6,042	$ 3	$ (6,572)	10,774	2,243	(406)	0
Increase (Decrease) in Stockholders' Equity
Net income	864
Unrealized gains on derivative instruments, net of tax	29
Defined benefit plan adjustments, net of income tax expense of $2, $—, $2, $—	4
Foreign currency translation, net of tax	$ (539)
Ending balance (in shares) at Sep. 30, 2022	185.8	256.3	70.5
Ending balance at Sep. 30, 2022	$ 5,347	$ 3	$ (7,715)	10,850	3,107	(898)	0
Beginning balance (in shares) at Mar. 31, 2022		256.2	66.9
Beginning balance at Mar. 31, 2022	5,919	$ 3	$ (6,975)	10,742	2,568	(419)	0
Increase (Decrease) in Stockholders' Equity
Issuance of common stock (in shares)		0.1
Issuance of common stock	(2)			(2)
Repurchase of common stock (in shares)			(2.8)
Repurchase of common stock	(590)		$ (590)
Stock-based compensation	47			47
Net income	256				256
Unrealized gains on derivative instruments, net of tax	(7)					(7)
Defined benefit plan adjustments, net of income tax expense of $2, $—, $2, $—	(4)					(4)
Foreign currency translation, net of tax	(281)					(281)
Reclassification adjustments, net of tax	14					14
Ending balance (in shares) at Jun. 30, 2022		256.3	69.7
Ending balance at Jun. 30, 2022	5,352	$ 3	$ (7,565)	10,787	2,824	(697)	0
Increase (Decrease) in Stockholders' Equity
Issuance of common stock (in shares)		0
Issuance of common stock	(1)			(1)
Repurchase of common stock (in shares)			(0.8)
Repurchase of common stock	(150)		$ (150)
Stock-based compensation	64			64
Net income	283				283		0
Unrealized gains on derivative instruments, net of tax	6					6
Defined benefit plan adjustments, net of income tax expense of $2, $—, $2, $—	10					10
Foreign currency translation, net of tax	(218)					(218)	0
Reclassification adjustments, net of tax	$ 1					1
Ending balance (in shares) at Sep. 30, 2022	185.8	256.3	70.5
Ending balance at Sep. 30, 2022	$ 5,347	$ 3	$ (7,715)	$ 10,850	$ 3,107	$ (898)	$ 0

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The Company IQVIA Holdings Inc. (together with its subsidiaries, the “Company” or “IQVIA”) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. With approximately 85,000 employees, IQVIA conducts business in more than 100 countries. Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The balance sheet as of December 31, 2021 has been derived from the audited consolidated financial statements of the Company, but does not include all the disclosures required by GAAP. Recently Issued Accounting Standards Accounting pronouncements adopted

Revenues by Geography, Concentr

Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations	Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations The following tables represent revenues by geographic region and reportable segment for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, 2022 (in millions) Technology & Research & Contract Sales & Total Revenues: Americas $ 746 $ 960 $ 91 $ 1,797 Europe and Africa 503 488 40 1,031 Asia-Pacific 151 531 52 734 Total revenues $ 1,400 $ 1,979 $ 183 $ 3,562 Three Months Ended September 30, 2021 (in millions) Technology & Research & Contract Sales & Total Revenues: Americas $ 647 $ 942 $ 94 $ 1,683 Europe and Africa 529 448 42 1,019 Asia-Pacific 161 463 65 689 Total revenues $ 1,337 $ 1,853 $ 201 $ 3,391 Nine Months Ended September 30, 2022 (in millions) Technology & Research & Contract Sales & Total Revenues: Americas $ 2,143 $ 2,772 $ 270 $ 5,185 Europe and Africa 1,639 1,527 129 3,295 Asia-Pacific 465 1,564 162 2,191 Total revenues $ 4,247 $ 5,863 $ 561 $ 10,671 Nine Months Ended September 30, 2021 (in millions) Technology & Research & Contract Sales & Total Revenues: Americas $ 1,882 $ 2,911 $ 258 $ 5,051 Europe and Africa 1,684 1,398 133 3,215 Asia-Pacific 472 1,303 197 1,972 Total revenues $ 4,038 $ 5,612 $ 588 $ 10,238 No individual customer represented 10% or more of consolidated revenues for the three and nine months ended September 30, 2022 or 2021. Transaction Price Allocated to the Remaining Performance Obligations

Trade Accounts Receivable, Unbi

Trade Accounts Receivable, Unbilled Services and Unearned Income	9 Months Ended
	Sep. 30, 2022
Receivables [Abstract]
Trade Accounts Receivable, Unbilled Services and Unearned Income	Trade Accounts Receivable, Unbilled Services and Unearned Income Trade accounts receivables and unbilled services consist of the following: (in millions) September 30, 2022 December 31, 2021 Billed $ 1,145 $ 1,275 Unbilled services 1,526 1,309 Trade accounts receivable and unbilled services 2,671 2,584 Allowance for doubtful accounts (31) (33) Trade accounts receivable and unbilled services, net $ 2,640 $ 2,551 Unbilled services and unearned income were as follows: (in millions) September 30, 2022 December 31, 2021 Change Unbilled services $ 1,526 $ 1,309 $ 217 Unearned income (1,842) (1,825) (17) Net balance $ (316) $ (516) $ 200 Unbilled services, which is comprised of approximately 61% and 63% of unbilled receivables and 39% and 37% of contract assets as of September 30, 2022 and December 31, 2021, respectively, increased by $217 million as compared to December 31, 2021. Contract assets are unbilled services for which invoicing is based on the timing of certain milestones related to service contracts for clinical research whereas unbilled receivables are billable upon the passage of time. Unearned income increased by $17 million over the same period resulting in an increase of $200 million in the net balance of unbilled services and unearned income between December 31, 2021 and September 30, 2022. The change in the net balance is driven by the difference in timing of revenue recognition in accordance with ASC 606, Revenue from Contracts with Customers, primarily related to the Company’s Research & Development Solutions contracts (which is based on the percentage of costs incurred) versus the timing of invoicing, which is based on certain milestones.

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill The following is a summary of goodwill by reportable segment for the nine months ended September 30, 2022: (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Consolidated Balance as of December 31, 2021 $ 11,337 $ 1,802 $ 162 $ 13,301 Business combinations 503 236 — 739 Impact of foreign currency fluctuations and other (802) (46) (15) (863) Balance as of September 30, 2022 $ 11,038 $ 1,992 $ 147 $ 13,177

Derivatives

Derivatives	9 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives The fair values of the Company’s derivative instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table: (in millions) Balance Sheet Classification September 30, 2022 December 31, 2021 Assets Liabilities Notional Assets Liabilities Notional Derivatives designated as hedging instruments: Foreign exchange forward contracts Other current assets and liabilities $ — $ 15 $ 125 $ — $ 3 $ 110 Interest rate swaps Other current assets, other assets and liabilities 49 — 1,800 4 24 1,800 Total derivatives $ 49 $ 15 $ 4 $ 27 The pre-tax effect of the Company’s cash flow hedging instruments on other comprehensive income is summarized in the following table: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2022 2021 2022 2021 Foreign exchange forward contracts $ (5) $ (5) $ (12) $ (9) Interest rate swaps 14 4 69 17 Total $ 9 $ (1) $ 57 $ 8 The amount of foreign exchange gains related to the net investment hedge included in the cumulative translation adjustment component of accumulated other comprehensive (loss) income (“AOCI”) for the nine months ended September 30, 2022 and 2021 was $807 million and $332 million, respectively.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company records certain assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. The carrying values of cash, cash equivalents, accounts receivable and accounts payable approximated their fair values as of September 30, 2022 and December 31, 2021 due to their short-term nature. As of September 30, 2022 and December 31, 2021, the fair value of total debt approximated $11,603 million and $12,255 million, respectively, as determined under Level 1 and Level 2 measurements for these financial instruments. Recurring Fair Value Measurements The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured and reported at fair value on a recurring basis as of September 30, 2022: (in millions) Level 1 Level 2 Level 3 Total Assets: Marketable securities $ 112 $ — $ — $ 112 Derivatives — 49 — 49 Total $ 112 $ 49 $ — $ 161 Liabilities: Derivatives $ — $ 15 $ — $ 15 Contingent consideration — — 95 95 Total $ — $ 15 $ 95 $ 110 Below is a summary of the valuation techniques used in determining fair value: Marketable securities — The Company values trading and available-for-sale securities using the quoted market value of the securities held. Derivatives — Derivatives consist of foreign exchange contracts and interest rate swaps. The fair value of foreign exchange contracts is based on observable market inputs of spot and forward rates or using other observable inputs. The fair value of the interest rate swaps is the estimated amount that the Company would receive or pay to terminate such agreements, taking into account market interest rates and the remaining time to maturities or using market inputs with mid-market pricing as a practical expedient for bid-ask spread. Contingent consideration — The Company values contingent consideration related to business combinations using a weighted probability calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Assumptions used to estimate the fair value of contingent consideration include various financial metrics (revenue performance targets and operating forecasts) and the probability of achieving the specific targets. Based on the assessments of the probability of achieving specific targets, as of September 30, 2022 the Company has accrued approximately 73% of the maximum contingent consideration payments that could potentially become payable. The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the nine months ended September 30: Contingent Consideration (in millions) 2022 2021 Balance as of January 1 $ 76 $ 119 Business combinations 54 39 Contingent consideration paid (18) (37) Revaluations included in earnings and foreign currency translation adjustments (17) (25) Balance as of September 30 $ 95 $ 96 The current portion of contingent consideration is included within accrued expenses and the long-term portion is included within other liabilities on the accompanying condensed consolidated balance sheets. Revaluations of contingent consideration are recognized in other expense (income), net on the accompanying condensed consolidated statements of income. A change in significant unobservable inputs could result in a higher or lower fair value measurement of contingent consideration. Non-recurring Fair Value Measurements

Credit Arrangements

Credit Arrangements	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Credit Arrangements	Credit Arrangements The following is a summary of the Company’s revolving credit facilities as of September 30, 2022: Facility Interest Rates $1,500 million (revolving credit facility) LIBOR in the relevant currency borrowed plus a margin of 1.25% as of September 30, 2022 $110 million (receivables financing facility) LIBOR Market Index Rate (3.14% as of September 30, 2022) plus 0.90% The following table summarizes the Company’s debt at the dates indicated: (dollars in millions) September 30, 2022 December 31, 2021 Revolving Credit Facility due 2026: U.S. Dollar denominated borrowings—U.S. Dollar LIBOR at average floating rates of —% $ — $ 100 Senior Secured Credit Facilities: Term A Loan due 2026—U.S. Dollar LIBOR at average floating rates of 4.92% 1,361 1,415 Term A Loan due 2026—Euribor at average floating rates of 2.44% 290 351 Term A Loan due 2027—U.S. Dollar SOFR at average floating rates of 4.90% 1,234 — Term B Loan due 2024—U.S. Dollar LIBOR at average floating rates of 4.87% 510 510 Term B Loan due 2024—Euribor at average floating rates of 3.19% 1,072 1,242 Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 4.87% 670 670 Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 5.42% 860 860 Term B Loan due 2025—Euribor at average floating rates of 3.19% 512 592 5.0% Senior Notes due 2027—U.S. Dollar denominated 1,100 1,100 5.0% Senior Notes due 2026—U.S. Dollar denominated 1,050 1,050 2.875% Senior Notes due 2025—Euro denominated 412 476 2.25% Senior Notes due 2028—Euro denominated 706 817 2.875% Senior Notes due 2028—Euro denominated 697 807 1.750% Senior Notes due 2026—Euro denominated 539 624 2.250% Senior Notes due 2029—Euro denominated 882 1,021 Receivables financing facility due 2024—U.S. Dollar LIBOR at average floating rates of 4.02%: Revolving Loan Commitment 110 110 Term Loan 440 440 Principal amount of debt 12,445 12,185 Less: unamortized discount and debt issuance costs (51) (60) Less: current portion (151) (91) Long-term debt $ 12,243 $ 12,034 Contractual maturities of long-term debt are as follows as of September 30, 2022: (in millions) Remainder of 2022 $ 38 2023 152 2024 2,283 2025 2,605 2026 3,017 Thereafter 4,350 $ 12,445 Senior Secured Credit Facilities On June 16, 2022, the Company entered into Amendment No. 1 to the Company’s Fifth Amended and Restated Credit Agreement (the “Credit Agreement”) to borrow $1,250 million in additional U.S. Dollar denominated term A loans due 2027 (the “Additional Term A Loans”). The Additional Term A Loans bear interest based at the Secured Overnight Financing Rate term rates (“Term SOFR”), plus a credit spread adjustment of 0.10% plus a margin ranging from 1.125% to 2.00%, with a Term SOFR floor of 0.00% per annum. The proceeds from the Additional Term A Loans were used to repay approximately $950 million of outstanding revolving credit loans under the Company’s Credit Agreement and for general corporate purposes. As of September 30, 2022, the Company’s Credit Agreement provided financing through several senior secured credit facilities of up to approximately $8,009 million, which consisted of $6,509 million principal amounts of debt outstanding (as detailed in the table above), and $1,500 million of available borrowing capacity on the $1,500 million revolving credit facility and standby letters of credit. The revolving credit facility is comprised of a $675 million senior secured revolving facility available in U.S. dollars, a $600 million senior secured revolving facility available in U.S. dollars, Euros, Swiss Francs and other foreign currencies, and a $225 million senior secured revolving facility available in U.S. dollars and Yen. Restrictive Covenants

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies The Company and its subsidiaries are involved in legal and tax proceedings, claims and litigation arising in the ordinary course of business. Management periodically assesses the Company’s liabilities and contingencies in connection with these matters based upon the latest information available. For those matters where management currently believes it is probable that the Company will incur a loss and that the probable loss or range of loss can be reasonably estimated, the Company has recorded an accrual in the consolidated financial statements based on its best estimates of such loss. In other instances, because of the uncertainties related to either the probable outcome or the amount or range of loss, management is unable to make a reasonable estimate of a liability, if any. However, even in many instances where the Company has recorded an estimated liability, the Company is unable to predict with certainty the final outcome of the matter or whether resolution of the matter will materially affect the Company’s results of operations, financial position or cash flows. As additional information becomes available, the Company adjusts its assessments and estimates of such liabilities accordingly. The Company routinely enters into agreements with third parties, including its clients and suppliers, all in the normal course of business. In these agreements, the Company sometimes agrees to indemnify and hold harmless the other party for any damages such other party may suffer as a result of potential intellectual property infringement and other claims. The Company has not accrued a liability with respect to these matters generally, as the exposure is considered remote. Based on its review of the latest information available, management does not expect the impact of pending legal and tax proceedings, claims and litigation, either individually or in the aggregate, to have a material adverse effect on the Company’s results of operations, cash flows or financial position. However, one or more unfavorable outcomes in any claim or litigation against the Company could have a material adverse effect for the period in which it is resolved. The following is a summary of certain legal matters involving the Company. On February 13, 2014, a group of approximately 1,200 medical doctors and 900 private individuals filed a civil lawsuit with the Seoul Central District Court against IMS Korea and two other defendants, the Korean Pharmaceutical Association (“KPA”) and the Korean Pharmaceutical Information Center (“KPIC”). The civil lawsuit alleges KPA and KPIC collected their personal information in violation of applicable privacy laws without the necessary consent through a software system installed on pharmacy computer systems in Korea, and that personal information was transferred to IMS Korea and sold to pharmaceutical companies. On September 11, 2017, the District Court issued a final decision that the encryption in use by the defendants since June 2014 was adequate to meet the requirements of the Korean Personal Information Privacy Act (“PIPA”) and the sharing of non-identified information for market research purposes was allowed under PIPA. The District Court also found an earlier version of encryption was insufficient to meet PIPA requirements, but no personal data had been leaked or re-identified. The District Court did not award any damages to plaintiffs. Approximately 280 medical doctors and 200 private individuals appealed the District Court decision. On May 3, 2019, the Appellate Court issued a final decision in which it concluded all of the non-identified information transferred by KPIC to IMS Korea for market research purposes violated PIPA, but did not award any damages to plaintiffs (affirming the District Court’s decision on this latter point). On May 24, 2019, approximately 247 plaintiffs appealed the Appellate Court’s decision to the Supreme Court. The Company believes the appeal is without merit and is vigorously defending its position. On July 23, 2015, indictments were issued by the Seoul Central District Prosecutors’ Office in South Korea against 24 individuals and companies alleging improper handling of sensitive health information in violation of, among others, South Korea’s Personal Information Protection Act. IMS Korea and two of its employees were among the individuals and organizations indicted. Although there is no assertion that IMS Korea used patient identified health information in any of its offerings, prosecutors allege that certain of IMS Korea’s data suppliers should have obtained patient consent when they converted sensitive patient information into non-identified data and that IMS Korea had not taken adequate precautions to reduce the risk of re-identification. On February 14, 2020, the Seoul Central District Court acquitted IMS Korea and its two employees of the charges of improper handling of sensitive health information, and the Prosecutor's Office appealed. On December 23, 2021, the appellate court affirmed the judgment of the Seoul Central District Court. The Prosecutor's Office has appealed to the Supreme Court. The Company intends to vigorously defend its position on appeal. On January 10, 2017, Quintiles IMS Health Incorporated and IMS Software Services Ltd. (collectively “IQVIA Parties”), filed a lawsuit in the U.S. District Court for the District of New Jersey against Veeva Systems, Inc. (“Veeva”) alleging Veeva unlawfully used IQVIA Parties intellectual property to improve Veeva data offerings, to promote and market Veeva data offerings and to improve Veeva technology offerings. IQVIA Parties seek injunctive relief, appointment of a monitor, the award of compensatory and punitive damages and reimbursement of all litigation expenses, including reasonable attorneys’ fees and costs. On March 13, 2017, Veeva filed counterclaims alleging anticompetitive business practices in violation of the Sherman Act and state laws. Veeva claims damages in excess of $200 million, and is seeking punitive damages and litigation costs, including attorneys’ fees. We believe the counterclaims are without merit, reject all counterclaims raised by Veeva and intend to vigorously defend IQVIA Parties’ position and pursue our claims against Veeva. Since the initial filings, the parties have filed additional litigations against each other, primarily concerning the use of IQVIA data with various other Veeva products. The parties are engaged in the discovery process in connection with these lawsuits. On May 7, 2021, the Court issued an order and opinion (the “Order”) in which it found significant evidence that Veeva had (1) misappropriated IQVIA data and unlawfully used it to improve Veeva data offerings, (2) engaged in a cover-up by deleting significant evidence of its theft of IQVIA’s trade secrets, and (3) improperly withheld certain evidence in furtherance of a crime and/or fraud against IQVIA. The Court imposed five sanctions against Veeva, including ordering three separate adverse inference instructions be issued to the jury and that IQVIA be permitted to present evidence to the jury of Veeva’s destruction efforts. Veeva is currently appealing the Order. In 2016, IQVIA acquired Dimensions Healthcare LLC (“Dimensions”), a company operating in the Middle East that was engaged in a joint venture with MedImpact International LLC (“MedImpact International”). The joint venture was terminated in late 2017, and on January 23, 2018, MedImpact International brought an arbitration in Dubai against Dimensions alleging that Dimensions had obtained access to its intellectual property through its prior joint venture with MedImpact International and had used that access to misappropriate and misuse MedImpact International’s intellectual property. Dimensions was ordered to pay an immaterial amount of damages and attorneys’ fees, and enjoined from future use of certain claimed MedImpact International intellectual property. On September 26, 2019, MedImpact Healthcare Systems, Inc., MedImpact International, MedImpact International Hong Kong Ltd (collectively, “MedImpact”) filed suit in the U.S. District Court for the Southern District of California alleging that various IQVIA entities (IQVIA Inc., IQVIA AG, and IQVIA Ltd.) and two IQVIA employees in the Middle East misappropriated its intellectual property, in violation of, among other things, the U.S. Defend Trade Secrets Act (“DTSA”) and the Racketeer Influenced and Corrupt Organizations Act (“RICO”). In particular, MedImpact alleges that IQVIA acquired Dimensions to obtain access to MedImpact’s intellectual property and then used that access to misappropriate and misuse MedImpact's intellectual property. MedImpact claims damages of approximately $100 million and is seeking the trebling of its damages and reimbursement of its litigation expenses, including its attorneys’ fees. MedImpact further seeks to enjoin IQVIA from continuing to misuse its intellectual property. On October 7, 2022, the Court dismissed MedImpact’s RICO claims as well as all claims against IQVIA Inc., IQVIA Ltd., and one of the individual employee defendants. A trial date on the remaining claims is anticipated in 2023. IQVIA rejects all of the claims raised by MedImpact and is vigorously defending IQVIA’s position. On December 13, 2021, IQVIA filed suit against MedImpact in the same California federal court, alleging that MedImpact and a former executive misappropriated and misused IQVIA’s intellectual property received in the same prior joint venture, in violation of, among other things, the DTSA and RICO. IQVIA seeks treble damages in an unspecified amount, reimbursement of litigation expenses, including attorneys’ fees, and to enjoin MedImpact from continuing to misuse its intellectual property.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred Stock The Company is authorized to issue 1.0 million shares of preferred stock, $0.01 per share par value. No shares of preferred stock were issued or outstanding as of September 30, 2022 or December 31, 2021. Equity Repurchase Program On February 10, 2022, the Company’s Board of Directors (the “Board”) increased the stock repurchase authorization under the Company's equity repurchase program (the “Repurchase Program”) with respect to the repurchase of the Company’s common stock by an additional $2.0 billion, which increased the total amount that has been authorized under the Repurchase Program to $9.725 billion. The Repurchase Program does not obligate the Company to repurchase any particular amount of common stock, and it may be modified, extended, suspended or discontinued at any time. During the nine months ended September 30, 2022, the Company repurchased 5.3 million shares of its common stock for $1,143 million under the Repurchase Program. These amounts include approximately 0.2 million of shares valued at approximately $40 million, which were accrued for as of September 30, 2022 based on when the trade and settlement dates occurred. As of September 30, 2022, the Company has remaining authorization to repurchase up to approximately $1.4 billion of its common stock under the Repurchase Program. In addition, from time to time, the Company has repurchased and may continue to repurchase common stock through private or other transactions outside of the Repurchase Program.

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Business Combinations	Business CombinationsThe Company completed several individually immaterial acquisitions during the nine months ended September 30, 2022. The Company’s assessment of fair value, including the valuation of certain identified intangibles, and the purchase price allocation related to these acquisitions is preliminary and subject to change upon completion. Further adjustments may be necessary as additional information related to the fair values of assets acquired and liabilities assumed is assessed during the measurement period (up to one year from the acquisition date). The Company recorded goodwill from these acquisitions, primarily attributable to assembled workforce and expected synergies. The condensed consolidated financial statements include the results of the acquisitions subsequent to their respective closing dates. Pro forma information is not presented as pro forma results of operations would not be materially different to the actual results of operations of the Company. The following table provides certain preliminary financial information for these acquisitions: (in millions) September 30, 2022 Assets acquired: Cash and cash equivalents $ 25 Other assets 105 Goodwill 739 Other identifiable intangibles 403 Liabilities assumed: Other liabilities (87) Deferred income taxes, long-term (90) Net assets acquired (1) $ 1,095 (1) Net assets acquired includes contingent consideration and deferred purchase price of $58 million for the nine months ended September 30, 2022. The portion of goodwill deductible for income tax purposes was preliminarily assessed as $30 million. The following table provides a summary of the preliminary estimated fair value of certain intangible assets acquired: (in millions) Amortization Period September 30, 2022 Other identifiable intangibles: Customer relationships 1 - 17 years $ 311 Software and related assets 3 - 5 years 58 Backlog 1 - 4 years 14 Databases 5 years 11 Trade names 2 - 3 years 6 Non-compete agreements 3 years 3 Total Other identifiable intangibles $ 403

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring The Company has continued to take restructuring actions in 2022 to align its resources and reduce overcapacity to adapt to changing market conditions and integrate acquisitions. These actions include consolidating functional activities, eliminating redundant positions, and aligning resources with customer requirements. These restructuring actions are expected to continue into 2023. The following amounts were recorded for the restructuring plans: (in millions) Severance and Balance as of December 31, 2021 $ 30 Expense, net of reversals 15 Payments (22) Foreign currency translation and other (2) Balance as of September 30, 2022 $ 21 The reversals were due to changes in estimates primarily from the redeployment of staff and higher than expected voluntary terminations. Restructuring costs are not allocated to the Company’s reportable segments as they are not part of the segment performance measures regularly reviewed by management. The Company expects that the majority of the restructuring accruals as of September 30, 2022 will be paid in 2022 and 2023.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe effective income tax rate was 19.4% and 4.4% in the third quarter of 2022 and 2021, respectively, and 19.5% and 13.8% in the first nine months of 2022 and 2021, respectively. The effective income tax rate in the third quarter and the first nine months of 2022 and 2021 was favorably impacted by the Company recording a benefit related to the 2021 and 2020 U.S. Federal tax return position associated with Foreign Derived Intangible Income (“FDII”) and Global Intangible Low-Taxed Income (“GILTI”) tax credits of $6 million and $29 million, respectively. Additionally, the effective income tax rate in the third quarter and in the first nine months of 2022 and 2021 was favorably impacted as a result of excess tax benefits recognized upon settlement of share-based compensation awards. For the third quarter of 2022 and 2021 this impact was $1 million and $3 million, respectively, and for the first nine months of 2022 and 2021 this impact was $15 million and $26 million

Accumulated Other Comprehensive

Accumulated Other Comprehensive (Loss) Income	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Accumulated Other Comprehensive (Loss) Income	Accumulated Other Comprehensive (Loss) Income Below is a summary of the components of AOCI: (in millions) Foreign Derivative Defined Income Total Balance as of December 31, 2021 $ (570) $ (21) $ 5 $ 180 $ (406) Other comprehensive (loss) income before reclassifications (344) 39 6 (207) (506) Reclassification adjustments — 18 — (4) 14 Balance as of September 30, 2022 $ (914) $ 36 $ 11 $ (31) $ (898) Below is a summary of the adjustments for amounts reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item: (in millions) Affected Financial Statement Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Derivative instruments: Interest rate swaps Interest expense $ (9) $ (5) $ (16) $ (14) Foreign exchange forward contracts Revenues 8 1 (2) 5 Total before income taxes (1) (4) (18) (9) Income taxes — (1) (4) (2) Total net of income taxes $ (1) $ (3) $ (14) $ (7)

Segments

Segments	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Segments	Segments The following table presents the Company’s operations by reportable segment. The Company is managed through three reportable segments, Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides mission critical information, technology solutions and real world insights and services to the Company's life science clients. Research & Development Solutions, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. Contract Sales & Medical Solutions provides health care provider (including contract sales) and patient engagement services to both biopharmaceutical clients and the broader healthcare market. Certain costs are not allocated to our segments and are reported as general corporate and unallocated expenses. These costs primarily consist of stock-based compensation and expenses related to integration activities and acquisitions. The Company also does not allocate depreciation and amortization or impairment charges to its segments. Asset information by segment is not presented, as this measure is not used by the chief operating decision maker to assess the Company’s performance. The Company’s reportable segment information is presented below: Three Months Ended Nine Months Ended (in millions) 2022 2021 2022 2021 Revenues Technology & Analytics Solutions $ 1,400 $ 1,337 $ 4,247 $ 4,038 Research & Development Solutions 1,979 1,853 5,863 5,612 Contract Sales & Medical Solutions 183 201 561 588 Total revenues 3,562 3,391 10,671 10,238 Cost of revenues, exclusive of depreciation and amortization Technology & Analytics Solutions 828 795 2,490 2,415 Research & Development Solutions 1,335 1,291 4,005 3,967 Contract Sales & Medical Solutions 158 167 480 487 Total cost of revenues, exclusive of depreciation and amortization 2,321 2,253 6,975 6,869 Selling, general and administrative expenses Technology & Analytics Solutions 213 199 628 579 Research & Development Solutions 199 198 614 576 Contract Sales & Medical Solutions 17 14 48 41 General corporate and unallocated 88 87 198 226 Total selling, general and administrative expenses 517 498 1,488 1,422 Segment profit Technology & Analytics Solutions 359 343 1,129 1,044 Research & Development Solutions 445 364 1,244 1,069 Contract Sales & Medical Solutions 8 20 33 60 Total segment profit 812 727 2,406 2,173 General corporate and unallocated (88) (87) (198) (226) Depreciation and amortization (248) (336) (773) (1,002) Restructuring costs (4) (2) (15) (15) Total income from operations $ 472 $ 302 $ 1,420 $ 930

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share The following table reconciles the basic to diluted weighted average shares outstanding: Three Months Ended September 30, Nine Months Ended September 30, (in millions, except per share data) 2022 2021 2022 2021 Numerator: Net income attributable to IQVIA Holdings Inc. $ 283 $ 261 $ 864 $ 648 Denominator: Basic weighted average common shares outstanding 186.5 191.5 188.3 191.5 Effect of dilutive stock options and share awards 2.9 3.8 3.0 3.5 Diluted weighted average common shares outstanding 189.4 195.3 191.3 195.0 Earnings per share attributable to common stockholders: Basic $ 1.52 $ 1.36 $ 4.59 $ 3.38 Diluted $ 1.49 $ 1.34 $ 4.52 $ 3.32 Stock-based awards will have a dilutive effect under the treasury method when the respective period's average market value of the Company's common stock exceeds the exercise proceeds. Performance awards are included in diluted earnings per share based on if the performance targets have been met at the end of the reporting period.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsOn October 13, 2022, the Company elected to prepay $510 million, the entire outstanding balance, of its U.S. Dollar Term B Loan due 2024.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The balance sheet as of December 31, 2021 has been derived from the audited consolidated financial statements of the Company, but does not include all the disclosures required by GAAP.
Recently Issued Accounting Standards	Recently Issued Accounting Standards Accounting pronouncements adopted

Revenues by Geography, Concen_2

Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations (Tables)	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Summary of Revenues by Geographic Region and Reportable Segment	The following tables represent revenues by geographic region and reportable segment for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, 2022 (in millions) Technology & Research & Contract Sales & Total Revenues: Americas $ 746 $ 960 $ 91 $ 1,797 Europe and Africa 503 488 40 1,031 Asia-Pacific 151 531 52 734 Total revenues $ 1,400 $ 1,979 $ 183 $ 3,562 Three Months Ended September 30, 2021 (in millions) Technology & Research & Contract Sales & Total Revenues: Americas $ 647 $ 942 $ 94 $ 1,683 Europe and Africa 529 448 42 1,019 Asia-Pacific 161 463 65 689 Total revenues $ 1,337 $ 1,853 $ 201 $ 3,391 Nine Months Ended September 30, 2022 (in millions) Technology & Research & Contract Sales & Total Revenues: Americas $ 2,143 $ 2,772 $ 270 $ 5,185 Europe and Africa 1,639 1,527 129 3,295 Asia-Pacific 465 1,564 162 2,191 Total revenues $ 4,247 $ 5,863 $ 561 $ 10,671 Nine Months Ended September 30, 2021 (in millions) Technology & Research & Contract Sales & Total Revenues: Americas $ 1,882 $ 2,911 $ 258 $ 5,051 Europe and Africa 1,684 1,398 133 3,215 Asia-Pacific 472 1,303 197 1,972 Total revenues $ 4,038 $ 5,612 $ 588 $ 10,238

Trade Accounts Receivable, Un_2

Trade Accounts Receivable, Unbilled Services and Unearned Income (Tables)	9 Months Ended
	Sep. 30, 2022
Receivables [Abstract]
Schedule of Trade Accounts Receivable and Unbilled Services	Trade accounts receivables and unbilled services consist of the following: (in millions) September 30, 2022 December 31, 2021 Billed $ 1,145 $ 1,275 Unbilled services 1,526 1,309 Trade accounts receivable and unbilled services 2,671 2,584 Allowance for doubtful accounts (31) (33) Trade accounts receivable and unbilled services, net $ 2,640 $ 2,551
Schedule of Net Contract Assets (Liabilities)	Unbilled services and unearned income were as follows: (in millions) September 30, 2022 December 31, 2021 Change Unbilled services $ 1,526 $ 1,309 $ 217 Unearned income (1,842) (1,825) (17) Net balance $ (316) $ (516) $ 200

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Goodwill by Reportable Segment	The following is a summary of goodwill by reportable segment for the nine months ended September 30, 2022: (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Consolidated Balance as of December 31, 2021 $ 11,337 $ 1,802 $ 162 $ 13,301 Business combinations 503 236 — 739 Impact of foreign currency fluctuations and other (802) (46) (15) (863) Balance as of September 30, 2022 $ 11,038 $ 1,992 $ 147 $ 13,177

Derivatives (Tables)

Derivatives (Tables)	9 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Fair Values of Derivative Instruments Designated as Hedges	The fair values of the Company’s derivative instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table: (in millions) Balance Sheet Classification September 30, 2022 December 31, 2021 Assets Liabilities Notional Assets Liabilities Notional Derivatives designated as hedging instruments: Foreign exchange forward contracts Other current assets and liabilities $ — $ 15 $ 125 $ — $ 3 $ 110 Interest rate swaps Other current assets, other assets and liabilities 49 — 1,800 4 24 1,800 Total derivatives $ 49 $ 15 $ 4 $ 27
Schedule of Effect of Cash Flow Hedging Instruments on Other Comprehensive (Loss) Income	The pre-tax effect of the Company’s cash flow hedging instruments on other comprehensive income is summarized in the following table: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2022 2021 2022 2021 Foreign exchange forward contracts $ (5) $ (5) $ (12) $ (9) Interest rate swaps 14 4 69 17 Total $ 9 $ (1) $ 57 $ 8

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Summary of Fair Value of Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured and reported at fair value on a recurring basis as of September 30, 2022: (in millions) Level 1 Level 2 Level 3 Total Assets: Marketable securities $ 112 $ — $ — $ 112 Derivatives — 49 — 49 Total $ 112 $ 49 $ — $ 161 Liabilities: Derivatives $ — $ 15 $ — $ 15 Contingent consideration — — 95 95 Total $ — $ 15 $ 95 $ 110
Schedule of Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the nine months ended September 30: Contingent Consideration (in millions) 2022 2021 Balance as of January 1 $ 76 $ 119 Business combinations 54 39 Contingent consideration paid (18) (37) Revaluations included in earnings and foreign currency translation adjustments (17) (25) Balance as of September 30 $ 95 $ 96

Credit Arrangements (Tables)

Credit Arrangements (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Summary of Credit Facilities	The following is a summary of the Company’s revolving credit facilities as of September 30, 2022: Facility Interest Rates $1,500 million (revolving credit facility) LIBOR in the relevant currency borrowed plus a margin of 1.25% as of September 30, 2022 $110 million (receivables financing facility) LIBOR Market Index Rate (3.14% as of September 30, 2022) plus 0.90%
Summary of Debt	The following table summarizes the Company’s debt at the dates indicated: (dollars in millions) September 30, 2022 December 31, 2021 Revolving Credit Facility due 2026: U.S. Dollar denominated borrowings—U.S. Dollar LIBOR at average floating rates of —% $ — $ 100 Senior Secured Credit Facilities: Term A Loan due 2026—U.S. Dollar LIBOR at average floating rates of 4.92% 1,361 1,415 Term A Loan due 2026—Euribor at average floating rates of 2.44% 290 351 Term A Loan due 2027—U.S. Dollar SOFR at average floating rates of 4.90% 1,234 — Term B Loan due 2024—U.S. Dollar LIBOR at average floating rates of 4.87% 510 510 Term B Loan due 2024—Euribor at average floating rates of 3.19% 1,072 1,242 Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 4.87% 670 670 Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 5.42% 860 860 Term B Loan due 2025—Euribor at average floating rates of 3.19% 512 592 5.0% Senior Notes due 2027—U.S. Dollar denominated 1,100 1,100 5.0% Senior Notes due 2026—U.S. Dollar denominated 1,050 1,050 2.875% Senior Notes due 2025—Euro denominated 412 476 2.25% Senior Notes due 2028—Euro denominated 706 817 2.875% Senior Notes due 2028—Euro denominated 697 807 1.750% Senior Notes due 2026—Euro denominated 539 624 2.250% Senior Notes due 2029—Euro denominated 882 1,021 Receivables financing facility due 2024—U.S. Dollar LIBOR at average floating rates of 4.02%: Revolving Loan Commitment 110 110 Term Loan 440 440 Principal amount of debt 12,445 12,185 Less: unamortized discount and debt issuance costs (51) (60) Less: current portion (151) (91) Long-term debt $ 12,243 $ 12,034
Schedule of Contractual Maturities of Long-term Debt	Contractual maturities of long-term debt are as follows as of September 30, 2022: (in millions) Remainder of 2022 $ 38 2023 152 2024 2,283 2025 2,605 2026 3,017 Thereafter 4,350 $ 12,445

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table provides certain preliminary financial information for these acquisitions: (in millions) September 30, 2022 Assets acquired: Cash and cash equivalents $ 25 Other assets 105 Goodwill 739 Other identifiable intangibles 403 Liabilities assumed: Other liabilities (87) Deferred income taxes, long-term (90) Net assets acquired (1) $ 1,095 (1) Net assets acquired includes contingent consideration and deferred purchase price of $58 million for the nine months ended September 30, 2022.
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination	The following table provides a summary of the preliminary estimated fair value of certain intangible assets acquired: (in millions) Amortization Period September 30, 2022 Other identifiable intangibles: Customer relationships 1 - 17 years $ 311 Software and related assets 3 - 5 years 58 Backlog 1 - 4 years 14 Databases 5 years 11 Trade names 2 - 3 years 6 Non-compete agreements 3 years 3 Total Other identifiable intangibles $ 403

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Summary of Amounts Recorded for Restructuring Plans	The following amounts were recorded for the restructuring plans: (in millions) Severance and Balance as of December 31, 2021 $ 30 Expense, net of reversals 15 Payments (22) Foreign currency translation and other (2) Balance as of September 30, 2022 $ 21

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive (Loss) Income (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Summary of Components of AOCI	Below is a summary of the components of AOCI: (in millions) Foreign Derivative Defined Income Total Balance as of December 31, 2021 $ (570) $ (21) $ 5 $ 180 $ (406) Other comprehensive (loss) income before reclassifications (344) 39 6 (207) (506) Reclassification adjustments — 18 — (4) 14 Balance as of September 30, 2022 $ (914) $ 36 $ 11 $ (31) $ (898)
Summary of Adjustments for (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item	Below is a summary of the adjustments for amounts reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item: (in millions) Affected Financial Statement Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Derivative instruments: Interest rate swaps Interest expense $ (9) $ (5) $ (16) $ (14) Foreign exchange forward contracts Revenues 8 1 (2) 5 Total before income taxes (1) (4) (18) (9) Income taxes — (1) (4) (2) Total net of income taxes $ (1) $ (3) $ (14) $ (7)

Segments (Tables)

Segments (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Reconciliation of Revenues and Income from Segments to Consolidated	Asset information by segment is not presented, as this measure is not used by the chief operating decision maker to assess the Company’s performance. The Company’s reportable segment information is presented below: Three Months Ended Nine Months Ended (in millions) 2022 2021 2022 2021 Revenues Technology & Analytics Solutions $ 1,400 $ 1,337 $ 4,247 $ 4,038 Research & Development Solutions 1,979 1,853 5,863 5,612 Contract Sales & Medical Solutions 183 201 561 588 Total revenues 3,562 3,391 10,671 10,238 Cost of revenues, exclusive of depreciation and amortization Technology & Analytics Solutions 828 795 2,490 2,415 Research & Development Solutions 1,335 1,291 4,005 3,967 Contract Sales & Medical Solutions 158 167 480 487 Total cost of revenues, exclusive of depreciation and amortization 2,321 2,253 6,975 6,869 Selling, general and administrative expenses Technology & Analytics Solutions 213 199 628 579 Research & Development Solutions 199 198 614 576 Contract Sales & Medical Solutions 17 14 48 41 General corporate and unallocated 88 87 198 226 Total selling, general and administrative expenses 517 498 1,488 1,422 Segment profit Technology & Analytics Solutions 359 343 1,129 1,044 Research & Development Solutions 445 364 1,244 1,069 Contract Sales & Medical Solutions 8 20 33 60 Total segment profit 812 727 2,406 2,173 General corporate and unallocated (88) (87) (198) (226) Depreciation and amortization (248) (336) (773) (1,002) Restructuring costs (4) (2) (15) (15) Total income from operations $ 472 $ 302 $ 1,420 $ 930

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table reconciles the basic to diluted weighted average shares outstanding: Three Months Ended September 30, Nine Months Ended September 30, (in millions, except per share data) 2022 2021 2022 2021 Numerator: Net income attributable to IQVIA Holdings Inc. $ 283 $ 261 $ 864 $ 648 Denominator: Basic weighted average common shares outstanding 186.5 191.5 188.3 191.5 Effect of dilutive stock options and share awards 2.9 3.8 3.0 3.5 Diluted weighted average common shares outstanding 189.4 195.3 191.3 195.0 Earnings per share attributable to common stockholders: Basic $ 1.52 $ 1.36 $ 4.59 $ 3.38 Diluted $ 1.49 $ 1.34 $ 4.52 $ 3.32

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) Employee in Thousands	Sep. 30, 2022 Employee Country
Summary Of Significant Accounting Policies [Line Items]
Number of employees | Employee	85
Minimum
Summary Of Significant Accounting Policies [Line Items]
Number of countries (more than) | Country	100

Revenues by Geography, Concen_3

Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations - Summary of Revenues by Geographic Region and Reportable Segment (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue
Total revenues	$ 3,562	$ 3,391	$ 10,671	$ 10,238
Americas
Disaggregation of Revenue
Total revenues	1,797	1,683	5,185	5,051
Europe and Africa
Disaggregation of Revenue
Total revenues	1,031	1,019	3,295	3,215
Asia-Pacific
Disaggregation of Revenue
Total revenues	734	689	2,191	1,972
Technology & Analytics Solutions
Disaggregation of Revenue
Total revenues	1,400	1,337	4,247	4,038
Technology & Analytics Solutions | Americas
Disaggregation of Revenue
Total revenues	746	647	2,143	1,882
Technology & Analytics Solutions | Europe and Africa
Disaggregation of Revenue
Total revenues	503	529	1,639	1,684
Technology & Analytics Solutions | Asia-Pacific
Disaggregation of Revenue
Total revenues	151	161	465	472
Research & Development Solutions
Disaggregation of Revenue
Total revenues	1,979	1,853	5,863	5,612
Research & Development Solutions | Americas
Disaggregation of Revenue
Total revenues	960	942	2,772	2,911
Research & Development Solutions | Europe and Africa
Disaggregation of Revenue
Total revenues	488	448	1,527	1,398
Research & Development Solutions | Asia-Pacific
Disaggregation of Revenue
Total revenues	531	463	1,564	1,303
Contract Sales & Medical Solutions
Disaggregation of Revenue
Total revenues	183	201	561	588
Contract Sales & Medical Solutions | Americas
Disaggregation of Revenue
Total revenues	91	94	270	258
Contract Sales & Medical Solutions | Europe and Africa
Disaggregation of Revenue
Total revenues	40	42	129	133
Contract Sales & Medical Solutions | Asia-Pacific
Disaggregation of Revenue
Total revenues	$ 52	$ 65	$ 162	$ 197

Revenues by Geography, Concen_4

Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations - Additional Information (Detail) - Customer	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Number of customer accounting for ten percent or more of revenue	0	0	0	0

Revenues by Geography, Concen_5

Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations - Future Obligation Terms (Detail) $ in Billions	Sep. 30, 2022 USD ($)
Disaggregation of Revenue
Revenue expected to be recognized in future from remaining performance obligations	$ 27.9
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01
Disaggregation of Revenue
Percentage of remaining performance obligations on which revenue is expected to be recognized (in percent)	30%
Unearned income recognition period	12 months

Trade Accounts Receivable, Un_3

Trade Accounts Receivable, Unbilled Services and Unearned Income - Trade Accounts Receivable and Unbilled Services (Detail) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Receivables, Net, Current [Abstract]
Billed	$ 1,145	$ 1,275
Unbilled services	1,526	1,309
Trade accounts receivable and unbilled services	2,671	2,584
Allowance for doubtful accounts	(31)	(33)
Trade accounts receivable and unbilled services, net	$ 2,640	$ 2,551

Trade Accounts Receivable, Un_4

Trade Accounts Receivable, Unbilled Services and Unearned Income - Schedule of Net Contract Assets (Liabilities) (Detail) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Unbilled Contracts Receivables
Unbilled services, beginning balance	$ 1,309
Change	217
Unbilled services, ending balance	1,526
Unearned Income
Unearned income, beginning balance	(1,825)
Change	(17)
Unearned income, ending balance	(1,842)
Net change in balance	200
Net balance, beginning balance	$ (316)	$ (516)

Trade Accounts Receivable, Un_5

Trade Accounts Receivable, Unbilled Services and Unearned Income - Additional Information (Detail) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Receivables [Abstract]
Unbilled receivables (percentage)	61%	63%
Contract assets (percentage)	39%	37%
Increase in unbilled services	$ 217
Decrease in unearned income	17
Net change in balance	$ 200

Goodwill - Summary of Goodwill

Goodwill - Summary of Goodwill by Reportable Segment (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Goodwill
Beginning balance	$ 13,301
Business combinations	739
Impact of foreign currency fluctuations and other	(863)
Ending balance	13,177
Technology & Analytics Solutions
Goodwill
Beginning balance	11,337
Business combinations	503
Impact of foreign currency fluctuations and other	(802)
Ending balance	11,038
Research & Development Solutions
Goodwill
Beginning balance	1,802
Business combinations	236
Impact of foreign currency fluctuations and other	(46)
Ending balance	1,992
Contract Sales & Medical Solutions
Goodwill
Beginning balance	162
Business combinations	0
Impact of foreign currency fluctuations and other	(15)
Ending balance	$ 147

Derivatives - Summary of Fair V

Derivatives - Summary of Fair Values of Derivative Instruments Designated as Hedges (Detail) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Derivatives, Fair Value
Assets	$ 49,000,000	$ 4,000,000
Liabilities	15,000,000	27,000,000
Derivatives designated as hedging instruments: | Other current assets and liabilities | Foreign exchange forward contracts
Derivatives, Fair Value
Assets	0	0
Liabilities	15,000,000	3,000,000
Notional	125,000,000	110,000,000
Derivatives designated as hedging instruments: | Other current assets, other assets and liabilities | Interest rate swaps
Derivatives, Fair Value
Assets	49,000,000	4,000,000
Liabilities	0	24,000,000
Notional	$ 1,800,000,000	$ 1,800,000,000

Derivatives - Effect of Cash Fl

Derivatives - Effect of Cash Flow Hedging Instruments on Other Comprehensive (Loss) Income (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosures
Effect of cash flow hedging instruments on other comprehensive (loss) income	$ 9	$ (1)	$ 57	$ 8
Foreign exchange forward contracts
Derivative Instruments and Hedging Activities Disclosures
Effect of cash flow hedging instruments on other comprehensive (loss) income	(5)	(5)	(12)	(9)
Interest rate swaps
Derivative Instruments and Hedging Activities Disclosures
Effect of cash flow hedging instruments on other comprehensive (loss) income	$ 14	$ 4	$ 69	$ 17

Derivatives - Additional Inform

Derivatives - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Foreign exchange loss related to net investment hedge	$ 807	$ 332

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Percentage accrued of maximum consideration payments to become payable	73%
Other identifiable intangibles, net	$ 4,718	$ 4,943
Level 1 and Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of total debt	11,603	$ 12,255
Level 3 | Fair Value, Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Assets, Fair Value Disclosure	18,021
Cost and equity method investments	126
Goodwill	13,177
Other identifiable intangibles, net	$ 4,718

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Assets:
Marketable securities	$ 87	$ 111
Derivatives	49	$ 4
Recurring Fair Value Measurements
Assets:
Marketable securities	112
Derivatives	49
Total	161
Liabilities:
Derivatives	15
Contingent consideration	95
Total	110
Recurring Fair Value Measurements | Level 1
Assets:
Marketable securities	112
Derivatives	0
Total	112
Liabilities:
Derivatives	0
Contingent consideration	0
Total	0
Recurring Fair Value Measurements | Level 2
Assets:
Marketable securities	0
Derivatives	49
Total	49
Liabilities:
Derivatives	15
Contingent consideration	0
Total	15
Recurring Fair Value Measurements | Level 3
Assets:
Marketable securities	0
Derivatives	0
Total	0
Liabilities:
Derivatives	0
Contingent consideration	95
Total	$ 95

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Contingent consideration - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation
Beginning balance	$ 76	$ 119
Business combinations	54	39
Contingent consideration paid	(18)	(37)
Revaluations included in earnings and foreign currency translation adjustments	(17)	(25)
Ending balance	$ 95	$ 96

Credit Arrangements - Summary o

Credit Arrangements - Summary of Credit Facilities (Detail)	9 Months Ended
	Sep. 30, 2022 USD ($)
Revolving Credit Facility | USD Revolving Credit Facility
Line of Credit Facility
Interest rate description	LIBOR in the relevant currency borrowed plus a margin of 1.25% as of September 30, 2022
Facility	$ 1,500,000,000
Revolving Credit Facility | USD Revolving Credit Facility | LIBOR
Line of Credit Facility
Rate	1.25%
Facility | Receivables Financing Facility
Line of Credit Facility
Interest rate description	LIBOR Market Index Rate (3.14% as of September 30, 2022) plus 0.90%
Facility	$ 110,000,000
Rate	3.14%
Facility | Receivables Financing Facility | LIBOR
Line of Credit Facility
Interest rate spread on base rate	0.90%

Credit Arrangements - Summary_2

Credit Arrangements - Summary of Debt (Detail) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Senior Secured Credit Facilities:
Principal amount of debt	$ 12,445	$ 12,185
Less: unamortized discount and debt issuance costs	(51)	(60)
Less: current portion	(151)	(91)
Long-term debt	12,243	12,034
U.S Dollars | Senior Secured Term A Loan, 3.03% | SOFR
Senior Secured Credit Facilities:
Principal amount of debt	$ 1,234	0
Average floating rate	4.90%
U.S Dollars | Term Loan | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 440	440
U.S Dollars | Due in 2024 | Senior Secured Term B Loan, 1.85% | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 510	510
Average floating rate	4.87%
U.S Dollars | Due in 2024 | Receivable Financing Facilities | LIBOR
Senior Secured Credit Facilities:
Average floating rate	4.02%
U.S Dollars | Due in 2025 | Senior Secured Term B Loan, 1.85% | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 670	670
Average floating rate	4.87%
U.S Dollars | Due in 2025 | Senior Secured Term B Loan 1.97% | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 860	860
Average floating rate	5.42%
U.S Dollars | Due in 2026 | Senior Secured Term A Loan, 1.47% | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 1,361	1,415
Average floating rate	4.92%
U.S Dollars | Due in 2026 | 5.0% Senior Notes | Senior Notes
Senior Secured Credit Facilities:
Principal amount of debt	$ 1,050	1,050
Rate	5%
U.S Dollars | Due in 2027 | 5.0% Senior Notes | Senior Notes
Senior Secured Credit Facilities:
Principal amount of debt	$ 1,100	1,100
Rate	5%
EUR Dollars | Due in 2024 | Senior Secured Term B Loan, 2.00% | Euribor Rate
Senior Secured Credit Facilities:
Principal amount of debt	$ 1,072	1,242
Average floating rate	3.19%
EUR Dollars | Due in 2025 | Senior Secured Term B Loan, 2.00% | Euribor Rate
Senior Secured Credit Facilities:
Principal amount of debt	$ 512	592
Average floating rate	3.19%
EUR Dollars | Due in 2025 | 2.875% Senior Notes | Senior Notes
Senior Secured Credit Facilities:
Principal amount of debt	$ 412	476
Rate	2.875%
EUR Dollars | Due in 2026 | Senior Secured Term A Loan, 1.25% | Euribor Rate
Senior Secured Credit Facilities:
Principal amount of debt	$ 290	351
Average floating rate	2.44%
EUR Dollars | Due in 2026 | 1.75% Senior Notes | Senior Notes
Senior Secured Credit Facilities:
Principal amount of debt	$ 539	624
Rate	1.75%
EUR Dollars | Due in 2028 | 2.875% Senior Notes | Senior Notes
Senior Secured Credit Facilities:
Principal amount of debt	$ 697	807
Rate	2.875%
EUR Dollars | Due in 2028 | 2.25% Senior Notes | Senior Notes
Senior Secured Credit Facilities:
Principal amount of debt	$ 706	817
Rate	2.25%
EUR Dollars | Due in 2029 | 2.25% Senior Notes | Senior Notes
Senior Secured Credit Facilities:
Principal amount of debt	$ 882	1,021
Rate	2.25%
Revolving Credit Facility | U.S Dollars | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 0	100
Average floating rate	0%
Revolving Credit Facility | U.S Dollars | Revolving Loan Commitment | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 110	$ 110

Credit Arrangements - Contractu

Credit Arrangements - Contractual Maturities of Long-term Debt (Detail) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Remainder of 2022	$ 38
2023	152
2024	2,283
2025	2,605
2026	3,017
Thereafter	4,350
Principal amount of debt	$ 12,445	$ 12,185

Credit Arrangements - Senior Se

Credit Arrangements - Senior Secured Credit Facilities (Detail) - USD ($) $ in Millions	Jun. 16, 2022	Sep. 30, 2022	Dec. 31, 2021
Line of Credit Facility
Principal amount of debt		$ 12,445	$ 12,185
Revolving Credit Facility
Line of Credit Facility
Repayments of debt	$ 950
Senior Secured Term A Loan, 3.03% | SOFR
Line of Credit Facility
Credit spread adjustment	0.10%
Term floor percentage	0%
Senior Secured Term A Loan, 3.03% | SOFR | Minimum
Line of Credit Facility
Interest rate spread on base rate	1.125%
Senior Secured Term A Loan, 3.03% | SOFR | Maximum
Line of Credit Facility
Interest rate spread on base rate	2%
Senior Secured Term A Loan, 3.03% | U.S Dollars | SOFR
Line of Credit Facility
Principal amount of debt		1,250
Senior Secured Credit Facilities, Fifth Amended and Restated Credit Agreement
Line of Credit Facility
Aggregate maximum principal amount		8,009
Principal amount		6,509
Senior Secured Credit Facilities, Revolving Credit Facility And Standby Letters Of Credit
Line of Credit Facility
Aggregate maximum principal amount		1,500
Available borrowing capacity		1,500
Senior Secured Credit Facilities, Revolving Credit Facility And Standby Letters Of Credit | U.S Dollars
Line of Credit Facility
Principal amount		675
Senior Secured Credit Facilities, Revolving Credit Facility And Standby Letters Of Credit | U.S. dollars, Euros, Swiss Francs And Other Foreign Currencies
Line of Credit Facility
Principal amount		600
Senior Secured Credit Facilities, Revolving Credit Facility And Standby Letters Of Credit | US Dollars And Yen
Line of Credit Facility
Principal amount		$ 225

Contingencies - Additional Info

Contingencies - Additional Information (Detail) $ in Millions	Jul. 14, 2020 private_individual	Sep. 26, 2019 USD ($) private_individual	May 24, 2019 medical_doctor	Sep. 11, 2017 medical_doctor	Sep. 11, 2017 private_individual	May 13, 2017 USD ($)	Jul. 23, 2015 private_individual	Feb. 13, 2014 medical_doctor	Feb. 13, 2014 private_individual	Feb. 13, 2014 Defendant
KPIC
Loss Contingencies
Number of plaintiffs			247	280	200			1,200	900
Number of defendants | Defendant										2
Seoul Central District Prosecutors
Loss Contingencies
Number of defendants							24
Seoul Central District Prosecutors | Employee
Loss Contingencies
Number of defendants	2						2
Veeva | Minimum
Loss Contingencies
Amount of damages claimed | $						$ 200
MedImpact
Loss Contingencies
Amount of damages claimed | $		$ 100
MedImpact | Employee
Loss Contingencies
Number of defendants		2

Stockholders' Equity (Detail)

Stockholders' Equity (Detail) - USD ($)		3 Months Ended						9 Months Ended
	Feb. 10, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Dec. 31, 2021
Class of Stock
Preferred stock, authorized (shares)		1,000,000						1,000,000
Preferred stock, par value (usd per share)		$ 0.01						$ 0.01
Preferred stock, shares issued (shares)		0						0	0
Preferred stock, shares outstanding (shares)		0						0	0
Repurchase of stock, value		$ 150,000,000	$ 590,000,000	$ 403,000,000	$ 125,000,000	$ 45,000,000	$ 62,000,000
Equity Repurchase Under Repurchase Program
Class of Stock
Equity repurchase program additional authorized amount	$ 2,000,000,000
Equity repurchase program authorized amount	$ 9,725,000,000
Repurchase of stock (in shares)								5,300,000
Repurchase of stock, value								$ 1,143,000,000
Equity available for repurchase under the repurchase program		$ 1,400,000,000						$ 1,400,000,000
Equity Repurchase Under Repurchase Program, Shares Accrued For
Class of Stock
Repurchase of stock (in shares)								200,000
Repurchase of stock, value								$ 40,000,000

Business Combinations - Schedul

Business Combinations - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Assets acquired:
Goodwill	$ 13,177	$ 13,301
Several Individually Immaterial Acquisitions
Assets acquired:
Cash and cash equivalents	25
Other assets	105
Goodwill	739
Other identifiable intangibles	403
Liabilities assumed:
Other liabilities	(87)
Deferred income taxes, long-term	(90)
Net assets acquired	1,095
Contingent consideration and deferred payments	$ 58

Business Combinations - Narrati

Business Combinations - Narrative (Details) $ in Millions	Sep. 30, 2022 USD ($)
Several Individually Immaterial Acquisitions
Business Acquisition [Line Items]
Portion of goodwill deductible for income tax purposes	$ 30

Business Combinations - Indefin

Business Combinations - Indefinite-Lived Intangible Assets Acquired as Part of Business Combination (Details) - Several Individually Immaterial Acquisitions $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Business Acquisition [Line Items]
Total Other identifiable intangibles	$ 403
Customer relationships
Business Acquisition [Line Items]
Total Other identifiable intangibles	$ 311
Non-compete agreements
Business Acquisition [Line Items]
Amortization Period	3 years
Total Other identifiable intangibles	$ 3
Software and related assets
Business Acquisition [Line Items]
Total Other identifiable intangibles	58
Trade names
Business Acquisition [Line Items]
Total Other identifiable intangibles	6
Backlog
Business Acquisition [Line Items]
Total Other identifiable intangibles	$ 14
Databases
Business Acquisition [Line Items]
Amortization Period	5 years
Total Other identifiable intangibles	$ 11
Minimum | Customer relationships
Business Acquisition [Line Items]
Amortization Period	1 year
Minimum | Software and related assets
Business Acquisition [Line Items]
Amortization Period	3 years
Minimum | Trade names
Business Acquisition [Line Items]
Amortization Period	2 years
Minimum | Backlog
Business Acquisition [Line Items]
Amortization Period	1 year
Maximum | Customer relationships
Business Acquisition [Line Items]
Amortization Period	17 years
Maximum | Software and related assets
Business Acquisition [Line Items]
Amortization Period	5 years
Maximum | Trade names
Business Acquisition [Line Items]
Amortization Period	3 years
Maximum | Backlog
Business Acquisition [Line Items]
Amortization Period	4 years

Restructuring - Summary of Amou

Restructuring - Summary of Amounts Recorded for Restructuring Plans (Detail) - Severance and Related Costs $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Restructuring Reserve
Restructuring reserves, beginning balance	$ 30
Expense, net of reversals	15
Payments	(22)
-2000000	(2)
Restructuring reserves, ending balance	$ 21

Income Taxes - Narratives (Deta

Income Taxes - Narratives (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Effective income tax rate (percent)	19.40%	4.40%	19.50%	13.80%
Tax cuts and jobs act, tax credit	$ 6	$ 29
Tax impact of share-based compensation awards	$ 1	$ 3	$ 15	$ 26

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive (Loss) Income - Summary of Components of AOCI (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Statement of Other Comprehensive Income
Beginning balance	$ 6,042
Ending balance	5,347
Income Taxes
Beginning balance	180
Other comprehensive (loss) income before reclassifications	(207)
Reclassification adjustments	(4)
Ending balance	(31)
Other comprehensive (loss) income before reclassifications	(506)
Reclassification adjustments	14
Foreign Currency Translation
Statement of Other Comprehensive Income
Beginning balance	(570)
Other comprehensive (loss) income before reclassifications	(344)
Reclassification adjustments	0
Ending balance	(914)
Derivative Instruments
Statement of Other Comprehensive Income
Beginning balance	(21)
Other comprehensive (loss) income before reclassifications	39
Reclassification adjustments	18
Ending balance	36
Defined Benefit Plans
Statement of Other Comprehensive Income
Beginning balance	5
Other comprehensive (loss) income before reclassifications	6
Reclassification adjustments	0
Ending balance	11
Total
Statement of Other Comprehensive Income
Beginning balance	(406)
Ending balance	$ (898)

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive (Loss) Income - Summary of Adjustments for (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Reclassification Adjustment out of Accumulated Other Comprehensive Income
Total before income taxes	$ (1)	$ (4)	$ (18)	$ (9)
Income taxes	0	(1)	(4)	(2)
Total net of income taxes	(1)	(3)	(14)	(7)
Interest rate swaps | Interest expense
Reclassification Adjustment out of Accumulated Other Comprehensive Income
Total before income taxes	(9)	(5)	(16)	(14)
Foreign exchange forward contracts | Revenues
Reclassification Adjustment out of Accumulated Other Comprehensive Income
Total before income taxes	$ 8	$ 1	$ (2)	$ 5

Segments - Additional Informati

Segments - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2022 Segment
Segment Reporting [Abstract]
Number of reportable segments	3

Segments - Operations by Report

Segments - Operations by Reportable Segments (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information
Revenues	$ 3,562	$ 3,391	$ 10,671	$ 10,238
Cost of revenues, exclusive of depreciation and amortization	2,321	2,253	6,975	6,869
Selling, general and administrative expenses	517	498	1,488	1,422
Segment profit	812	727	2,406	2,173
Depreciation and amortization	(248)	(336)	(773)	(1,002)
Restructuring costs	(4)	(2)	(15)	(15)
Income from operations	472	302	1,420	930
Technology & Analytics Solutions
Segment Reporting Information
Revenues	1,400	1,337	4,247	4,038
Cost of revenues, exclusive of depreciation and amortization	828	795	2,490	2,415
Segment profit	359	343	1,129	1,044
Research & Development Solutions
Segment Reporting Information
Revenues	1,979	1,853	5,863	5,612
Cost of revenues, exclusive of depreciation and amortization	1,335	1,291	4,005	3,967
Segment profit	445	364	1,244	1,069
Contract Sales & Medical Solutions
Segment Reporting Information
Revenues	183	201	561	588
Cost of revenues, exclusive of depreciation and amortization	158	167	480	487
Segment profit	8	20	33	60
Operating Segments | Technology & Analytics Solutions
Segment Reporting Information
Selling, general and administrative expenses	213	199	628	579
Operating Segments | Research & Development Solutions
Segment Reporting Information
Selling, general and administrative expenses	199	198	614	576
Operating Segments | Contract Sales & Medical Solutions
Segment Reporting Information
Selling, general and administrative expenses	17	14	48	41
General corporate and unallocated
Segment Reporting Information
Selling, general and administrative expenses	88	87	198	226
Segment profit	$ (88)	$ (87)	$ (198)	$ (226)

Earnings Per Share - Reconciles

Earnings Per Share - Reconciles the Basic to Diluted Weighted Average Shares Outstanding (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Net income attributable to IQVIA Holdings Inc.	$ 283	$ 261	$ 864	$ 648
Denominator:
Basic weighted average common shares outstanding (in shares)	186.5	191.5	188.3	191.5
Effect of dilutive stock options and share awards (in shares)	2.9	3.8	3	3.5
Diluted weighted average common shares outstanding (in shares)	189.4	195.3	191.3	195
Earnings per share attributable to common stockholders:
Basic (in dollars per share)	$ 1.52	$ 1.36	$ 4.59	$ 3.38
Diluted (in dollars per share)	$ 1.49	$ 1.34	$ 4.52	$ 3.32

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	0.4	0.9	0.5	0.9

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Millions	Oct. 13, 2022	Sep. 30, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Principal amount of debt		$ 12,445	$ 12,185
U.S Dollars | Senior Secured Term B Loan, 1.85% | Due in 2024 | LIBOR
Subsequent Event [Line Items]
Principal amount of debt		$ 510	$ 510
Subsequent Event | U.S Dollars | Senior Secured Term B Loan, 1.85% | Due in 2024 | LIBOR
Subsequent Event [Line Items]
Principal amount of debt	$ 510